Oestrogen and bone density: A comparison of tamoxifen and hypo-oestrogenaemia
The effect of the anti-oestrogen tamoxifen on bone density in post-menopausal women with stage II breast cancer (n = 35) was compared with two untreated hypo-oestrogenaemic groups (premature ovarian failure, n = 20; prolactinoma, n = 19) and a group of women with prolactinomas and normal oestrogen l...
Gespeichert in:
| Veröffentlicht in: | Nuclear medicine communications 1995-08, Vol.16 (8), p.698-702 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 702 |
|---|---|
| container_issue | 8 |
| container_start_page | 698 |
| container_title | Nuclear medicine communications |
| container_volume | 16 |
| creator | LESLIE, W D COWDEN, E A MACLEAN, J P |
| description | The effect of the anti-oestrogen tamoxifen on bone density in post-menopausal women with stage II breast cancer (n = 35) was compared with two untreated hypo-oestrogenaemic groups (premature ovarian failure, n = 20; prolactinoma, n = 19) and a group of women with prolactinomas and normal oestrogen levels (n = 12). Bone densities were normal in the euoestrogenaemic groups, but significantly reduced in both hypo-oestrogenaemic groups. Repeat measurements were available for 31 of the 35 tamoxifen-treated subjects after an interval of 33.9 ± 14.7 months. The anti-oestrogen action of tamoxifen was not associated with accelerated bone loss of the spine or hip, an outcome that was clearly demonstrable in hypo-oestrogenaemic disorders. |
| doi_str_mv | 10.1097/00006231-199508000-00013 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77614800</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77614800</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3293-c5128a46a5f1e4bd586ff9d715d9d615e4875a521d1a654a1750ffd42e9abef43</originalsourceid><addsrcrecordid>eNp1kU1P3DAQhq2qaLss_QmVckC9pWTiz3BDqFAkEBc4W7PxuBtI4q2dFd1_X7cb9lZLljWa57VHjxkroPoGVaMvqrxUzaGEppGVyVWZN_APbAlC81Kq2nxkywoEL7ni6hM7TeklI4YrvWALLRoAI5bs4ZHSFMNPGgscXbEOIxWOxtRN-8viqmjDsMXYpTAWwRcTDuF352d2s9-GMrzHkYYOz9iJxz7R5_lcseeb70_XP8r7x9u766v7suV1w8tWQm1QKJQeSKydNMr7xmmQrnEKJAmjJcoaHKCSAkHLynsnampwTV7wFft6uHcbw69dHsEOXWqp73GksEtWawUiW8mgOYBtDClF8nYbuwHj3kJl_5q07ybt0aT9ZzJHv8xv7NYDuWNwVpf753MfU4u9jzi2XTpi2boW3GRMHLC30E8U02u_e6NoN4T9tLH_-0f-B8vhios</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77614800</pqid></control><display><type>article</type><title>Oestrogen and bone density: A comparison of tamoxifen and hypo-oestrogenaemia</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>LESLIE, W D ; COWDEN, E A ; MACLEAN, J P</creator><creatorcontrib>LESLIE, W D ; COWDEN, E A ; MACLEAN, J P</creatorcontrib><description>The effect of the anti-oestrogen tamoxifen on bone density in post-menopausal women with stage II breast cancer (n = 35) was compared with two untreated hypo-oestrogenaemic groups (premature ovarian failure, n = 20; prolactinoma, n = 19) and a group of women with prolactinomas and normal oestrogen levels (n = 12). Bone densities were normal in the euoestrogenaemic groups, but significantly reduced in both hypo-oestrogenaemic groups. Repeat measurements were available for 31 of the 35 tamoxifen-treated subjects after an interval of 33.9 ± 14.7 months. The anti-oestrogen action of tamoxifen was not associated with accelerated bone loss of the spine or hip, an outcome that was clearly demonstrable in hypo-oestrogenaemic disorders.</description><identifier>ISSN: 0143-3636</identifier><identifier>EISSN: 1473-5628</identifier><identifier>DOI: 10.1097/00006231-199508000-00013</identifier><identifier>PMID: 7491184</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott-Raven Publishers</publisher><subject>Adult ; Analysis of Variance ; Antineoplastic Agents, Hormonal - therapeutic use ; Biological and medical sciences ; Bone Density - drug effects ; Breast Neoplasms - drug therapy ; Breast Neoplasms - physiopathology ; Female ; Follow-Up Studies ; Hormones. Endocrine system ; Humans ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Pituitary Neoplasms - physiopathology ; Postmenopause ; Primary Ovarian Insufficiency - physiopathology ; Prolactinoma - physiopathology ; Tamoxifen - therapeutic use ; Time Factors</subject><ispartof>Nuclear medicine communications, 1995-08, Vol.16 (8), p.698-702</ispartof><rights>Lippincott-Raven Publishers.</rights><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3637438$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7491184$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LESLIE, W D</creatorcontrib><creatorcontrib>COWDEN, E A</creatorcontrib><creatorcontrib>MACLEAN, J P</creatorcontrib><title>Oestrogen and bone density: A comparison of tamoxifen and hypo-oestrogenaemia</title><title>Nuclear medicine communications</title><addtitle>Nucl Med Commun</addtitle><description>The effect of the anti-oestrogen tamoxifen on bone density in post-menopausal women with stage II breast cancer (n = 35) was compared with two untreated hypo-oestrogenaemic groups (premature ovarian failure, n = 20; prolactinoma, n = 19) and a group of women with prolactinomas and normal oestrogen levels (n = 12). Bone densities were normal in the euoestrogenaemic groups, but significantly reduced in both hypo-oestrogenaemic groups. Repeat measurements were available for 31 of the 35 tamoxifen-treated subjects after an interval of 33.9 ± 14.7 months. The anti-oestrogen action of tamoxifen was not associated with accelerated bone loss of the spine or hip, an outcome that was clearly demonstrable in hypo-oestrogenaemic disorders.</description><subject>Adult</subject><subject>Analysis of Variance</subject><subject>Antineoplastic Agents, Hormonal - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Bone Density - drug effects</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - physiopathology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hormones. Endocrine system</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Pituitary Neoplasms - physiopathology</subject><subject>Postmenopause</subject><subject>Primary Ovarian Insufficiency - physiopathology</subject><subject>Prolactinoma - physiopathology</subject><subject>Tamoxifen - therapeutic use</subject><subject>Time Factors</subject><issn>0143-3636</issn><issn>1473-5628</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU1P3DAQhq2qaLss_QmVckC9pWTiz3BDqFAkEBc4W7PxuBtI4q2dFd1_X7cb9lZLljWa57VHjxkroPoGVaMvqrxUzaGEppGVyVWZN_APbAlC81Kq2nxkywoEL7ni6hM7TeklI4YrvWALLRoAI5bs4ZHSFMNPGgscXbEOIxWOxtRN-8viqmjDsMXYpTAWwRcTDuF352d2s9-GMrzHkYYOz9iJxz7R5_lcseeb70_XP8r7x9u766v7suV1w8tWQm1QKJQeSKydNMr7xmmQrnEKJAmjJcoaHKCSAkHLynsnampwTV7wFft6uHcbw69dHsEOXWqp73GksEtWawUiW8mgOYBtDClF8nYbuwHj3kJl_5q07ybt0aT9ZzJHv8xv7NYDuWNwVpf753MfU4u9jzi2XTpi2boW3GRMHLC30E8U02u_e6NoN4T9tLH_-0f-B8vhios</recordid><startdate>199508</startdate><enddate>199508</enddate><creator>LESLIE, W D</creator><creator>COWDEN, E A</creator><creator>MACLEAN, J P</creator><general>Lippincott-Raven Publishers</general><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199508</creationdate><title>Oestrogen and bone density: A comparison of tamoxifen and hypo-oestrogenaemia</title><author>LESLIE, W D ; COWDEN, E A ; MACLEAN, J P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3293-c5128a46a5f1e4bd586ff9d715d9d615e4875a521d1a654a1750ffd42e9abef43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adult</topic><topic>Analysis of Variance</topic><topic>Antineoplastic Agents, Hormonal - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Bone Density - drug effects</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - physiopathology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hormones. Endocrine system</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Pituitary Neoplasms - physiopathology</topic><topic>Postmenopause</topic><topic>Primary Ovarian Insufficiency - physiopathology</topic><topic>Prolactinoma - physiopathology</topic><topic>Tamoxifen - therapeutic use</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LESLIE, W D</creatorcontrib><creatorcontrib>COWDEN, E A</creatorcontrib><creatorcontrib>MACLEAN, J P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Nuclear medicine communications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LESLIE, W D</au><au>COWDEN, E A</au><au>MACLEAN, J P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oestrogen and bone density: A comparison of tamoxifen and hypo-oestrogenaemia</atitle><jtitle>Nuclear medicine communications</jtitle><addtitle>Nucl Med Commun</addtitle><date>1995-08</date><risdate>1995</risdate><volume>16</volume><issue>8</issue><spage>698</spage><epage>702</epage><pages>698-702</pages><issn>0143-3636</issn><eissn>1473-5628</eissn><abstract>The effect of the anti-oestrogen tamoxifen on bone density in post-menopausal women with stage II breast cancer (n = 35) was compared with two untreated hypo-oestrogenaemic groups (premature ovarian failure, n = 20; prolactinoma, n = 19) and a group of women with prolactinomas and normal oestrogen levels (n = 12). Bone densities were normal in the euoestrogenaemic groups, but significantly reduced in both hypo-oestrogenaemic groups. Repeat measurements were available for 31 of the 35 tamoxifen-treated subjects after an interval of 33.9 ± 14.7 months. The anti-oestrogen action of tamoxifen was not associated with accelerated bone loss of the spine or hip, an outcome that was clearly demonstrable in hypo-oestrogenaemic disorders.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott-Raven Publishers</pub><pmid>7491184</pmid><doi>10.1097/00006231-199508000-00013</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0143-3636 |
| ispartof | Nuclear medicine communications, 1995-08, Vol.16 (8), p.698-702 |
| issn | 0143-3636 1473-5628 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77614800 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adult Analysis of Variance Antineoplastic Agents, Hormonal - therapeutic use Biological and medical sciences Bone Density - drug effects Breast Neoplasms - drug therapy Breast Neoplasms - physiopathology Female Follow-Up Studies Hormones. Endocrine system Humans Medical sciences Middle Aged Pharmacology. Drug treatments Pituitary Neoplasms - physiopathology Postmenopause Primary Ovarian Insufficiency - physiopathology Prolactinoma - physiopathology Tamoxifen - therapeutic use Time Factors |
| title | Oestrogen and bone density: A comparison of tamoxifen and hypo-oestrogenaemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T19%3A38%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oestrogen%20and%20bone%20density:%20A%20comparison%20of%20tamoxifen%20and%20hypo-oestrogenaemia&rft.jtitle=Nuclear%20medicine%20communications&rft.au=LESLIE,%20W%20D&rft.date=1995-08&rft.volume=16&rft.issue=8&rft.spage=698&rft.epage=702&rft.pages=698-702&rft.issn=0143-3636&rft.eissn=1473-5628&rft_id=info:doi/10.1097/00006231-199508000-00013&rft_dat=%3Cproquest_cross%3E77614800%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77614800&rft_id=info:pmid/7491184&rfr_iscdi=true |